Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 7.99 is 33% below its 5-year average of 11.99, near the low end of its 5-year range (0.00–34.46).
As of the fiscal period ended Tuesday, June 30, 2026. 8.59% below its 12-month average of 8.74.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 7.99.
QUICK RATIO (ACID-TEST)
7.99
QUICK RATIO (ACID-TEST) AVG TTM
8.74
QUICK RATIO (ACID-TEST) AVG 3Y
11.00
QUICK RATIO (ACID-TEST) AVG 5Y
11.99
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.59%
CURRENT VS 3Y AVG
-27.36%
CURRENT VS 5Y AVG
-33.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+138.23%
vs the sector median at left
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$79.61M
Quick Ratio (Acid-Test)
7.99
TTM Avg
8.74
3Y Avg
11.00
5Y Avg
11.99
Market Cap
$79.03M
Quick Ratio (Acid-Test)
0.34
TTM Avg
0.10
3Y Avg
0.26
5Y Avg
0.26
Market Cap
$80.30M
Quick Ratio (Acid-Test)
5.74
TTM Avg
2.67
3Y Avg
4.44
5Y Avg
7.03
Market Cap
$78.59M
Quick Ratio (Acid-Test)
12.48
TTM Avg
10.44
3Y Avg
6.35
5Y Avg
4.72
Market Cap
$78.29M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.80
3Y Avg
2.98
5Y Avg
4.38
Market Cap
$78.07M
Quick Ratio (Acid-Test)
1.00
TTM Avg
2.08
3Y Avg
2.75
5Y Avg
4.86
Market Cap
$81.20M
Quick Ratio (Acid-Test)
4.02
TTM Avg
5.44
3Y Avg
3.75
5Y Avg
3.66
Market Cap
$81.22M
Quick Ratio (Acid-Test)
8.75
TTM Avg
11.02
3Y Avg
14.04
5Y Avg
18.21
Market Cap
$77.54M
Quick Ratio (Acid-Test)
0.14
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $79.61M | 7.99 | 8.74 | 11.00 | 11.99 |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | 0.34 | 0.10 | 0.26 | 0.26 |
| Humacyte, Inc. (HUMA)vs › | $80.30M | 5.74 | 2.67 | 4.44 | 7.03 |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | 12.48 | 10.44 | 6.35 | 4.72 |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | 1.98 | 1.80 | 2.98 | 4.38 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | 1.00 | 2.08 | 2.75 | 4.86 |
| Nutriband Inc. (NTRB)vs › | $81.20M | 4.02 | 5.44 | 3.75 | 3.66 |
| MediciNova, Inc. (MNOV)vs › | $81.22M | 8.75 | 11.02 | 14.04 | 18.21 |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | 0.14 | 0.07 | 0.07 | 0.07 |
| LENSAR Inc (LNSR)vs › | $82.29M | 1.13 | 1.33 | 1.81 | 2.82 |
Quick Ratio
7.99
Excludes inventory
Current Ratio
7.99
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 7.99 |
| 2026-03-31 | 8.98 |
| 2025-12-31 | 7.69 |
| 2025-09-30 | 8.75 |
| 2025-06-30 | 10.31 |
| 2025-03-31 | 11.17 |
| 2024-12-31 | 10.55 |
| 2024-09-30 | 12.75 |
| 2024-06-30 | 16.16 |
| 2024-03-31 | 12.40 |
| 2023-12-31 | 9.75 |
| 2023-09-30 | 15.54 |
| 2023-06-30 | 21.84 |
| 2023-03-31 | 21.82 |
| 2022-12-31 | 20.27 |
| 2022-09-30 | 12.31 |
| 2022-06-30 | 19.58 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 34.46 |
| 2021-09-30 | 0.00 |
